Dr. Shreela Sharma’s advice for eating well, moving more, and making goals stick in the New Year

Why a good night of sleep transforms Adam Brown's diabetes the next day

A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide

Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017

Leading scientists discuss areas of growth ranging from behavior to artificial intelligence at The diaTribe Foundation’s “Solvable Problems” event in Lisbon

Easy-to-use Bydureon pen cuts down on the hassle of once-weekly injections by offering convenient mixing, a hidden needle, and more​

The hardest chapter to write: my story

Express Scripts recently announced the launch of Inside Rx, a discount prescription program with savings ranging from 16% to nearly 80% for insulin and other diabetes...

Q&A with Bike Beyond riders on what got them through a 10-week cross country bike trip

Continuously delivers GLP-1 agonist for 3-6 months; FDA decision is expected by the end of 2017

Full results of DEVOTE study presented at ADA 2017 show that basal insulin Tresiba reduces risk of severe hypoglycemia by 40% (by 53% overnight), in addition to being...

Recall applies to sets manufactured before April 2017; Medtronic is replacing old sets that have a risk of insulin over-delivery

How Adam Brown learned to make low-carb food tasty, doable, portable, and fun. Plus, cool new diabetes food experiments he's been testing!

Lilly’s Humalog Junior KwikPen offers 0.5 unit dose increments in prefilled, disposable device – a win for highly insulin sensitive users

Key takeaways from the American Heart Association’s March 2017 conference in Portland, OR

The most popular diabetes app in the world, mySugr offers coaching and tools to track blood sugar, medications, exercise, and “makes diabetes suck less”

A real-world trial in 3,000+ participants currently enrolling participants with type 2 diabetes

The FDA officially approves the new, expanded indication for people with type 2 diabetes

New apps and software updates from mySugr, Insulia, One Drop, as well as food and weight loss apps

CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations